GlaxoSmithkline Consumer Healthcare – Margin will be around 18%

Highlights of the call The company’s sales for the quarter ended March 09 has increased by 31% to Rs 539.37 crore, supported by volume growth in Horlick by 21% and Boost by 8%. There was a overall volume growth of 20%. There was a price growth of around 7% for the quarter. A 3% excise … Read more GlaxoSmithkline Consumer Healthcare – Margin will be around 18%

Piramal Healthcare – Expects a revenue growth of 16-17% for FY’10

Piramal Healthcare posted 9% growth in net sales to Rs 850.91 crore for the quarter ended March 2009. Operating Profit margins crashed by 650 bps to 21.0% on the back of R & D expenses of Rs 20.18 crore as against R & D income of Rs 40.48 crore in the corresponding pervious period. Resulting … Read more Piramal Healthcare – Expects a revenue growth of 16-17% for FY’10

Idea Cellular Transfer of towers to Indus results in 2.2% contraction in EBIDTA

Highlights of the concall The company has recorded Rs 2936.49 crore consolidated revenue for Q4 FY09, 8% up Q-o-Q. The consolidated EBIDTA margins for Q4 FY09 improved 210 bps sequentially to 27.6%. At EBIDTA level, Spice and Indus have contributed Rs 69.4 crore for Q4 FY09. The consolidated PAT for the quarter stood at Rs … Read more Idea Cellular Transfer of towers to Indus results in 2.2% contraction in EBIDTA

Zee Entertainment Enterprises – Targets 10-15% bottomline growth for FY10

Zee Entertainment Enterprises (ZEEL) held a conference call to discuss results for the fourth quarter ended March 31, 2009. Mr Subhash Chandra, Chairman addressed the call. Highlights of the call For FY10, the management is not giving any revenue guidance on the back of current challenging environment. However, the management is confident of bottomline growth … Read more Zee Entertainment Enterprises – Targets 10-15% bottomline growth for FY10